Nicholas A. LaBella Jr., MS, RPh, has joined Insmed as chief scientific officer, a newly-created position on the executive team. Mr. LaBella will oversee the scientific and regulatory analysis related to the company’s ongoing strategic review. He reports to Dr. Melvin Sharoky, Insmed’s chairman.

Mr. LaBella has approximately 30 years of pharmaceutical industry experience, including drug development, clinical operations and regulatory affairs. Most recently, he served as vice president of development and regulatory affairs at Cardiokine, Inc., a privately-held specialty pharmaceutical company.

“Nick’s extensive track record in drug development, clinical operations and regulatory affairs should significantly benefit our strategic review process,” said Dr. Melvin Sharoky, Insmed’s chairman. “Nick recently served as a scientific consultant to Insmed and his counsel has been instrumental in our scientific evaluations.As we continue our review of late-stage development assets, adding Nick to the internal management team should further streamline the review process and add greater efficiency to the scientific and regulatory analysis of each asset.”